Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy;Adénomes à prolactine et estrogènes : grossesse, contraception, traitement hormonal estroprogestatif

Annales d'Endocrinologie

Volumn 68, Issue 2-3, 2007, Pages

  Christin Maitre S ^a   Delemer, B ^b   Touraine, P ^c   Young, J ^d  

^a HÔPITAL SAINT ANTOINE   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

Estrogens; Prolactinoma

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CONTRACEPTIVE AGENT; DIETHYLSTILBESTROL; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN DERIVATIVE; ETHINYLESTRADIOL; PROLACTIN; QUINAGOLIDE;

CELL HYPERPLASIA; CONTRACEPTION; ECTOPIC PREGNANCY; FETUS MALFORMATION; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; NONHUMAN; OVULATION; POSTMENOPAUSE; PREGNANCY; PRESCRIPTION; PROLACTINOMA; SHORT SURVEY; SPONTANEOUS ABORTION; TUMOR GROWTH; VOMITING;

EID: 34547791433     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2007.03.009     Document Type: Short Survey

References (41)

1. Asa S.L., Kelly M.A., Grandy D.K., and Low M.J. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice. Endocrinology 140 (1999) 5348-5355
2. Bricaire C., Kerlan V., Kutenn F., and Mauvais-Jarvis P. La grossesse, une modalité de guérison des adénomes à PRL ? Dix-huit observations. Presse Med. 17 (1998) 2117-2119
3. Brownell J. Quinagolide in hyperprolactinemia. Rev. Contemp. Pharmacother 9 (1998) 1-75
4. Chiodini I., and Liuzzi A. PRL-secreting pituitary adenomas in pregnancy. J. Endocrinol. Invest. 26 (2003) 96-99
5. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S., et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinemiea and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 20 (1997) 547-551
6. Corenblum B., and Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril. 59 3 (1993) 671-673
7. Crosignani P.G., Mattei A.M., Severini V., Cavioni V., Maggioni P., and Testa G. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 44 3 (1992) 175-180
8. Davis J.R.E. Prolactin and reproductive medicine. Curr. Opin. Obstet. Gynecol. 16 (2004) 331-337
9. Delgrange E., Trouillas J., Maiter D., Donckier J., and Tourniaire J. Sex-related difference in the growth of prolactinomas: a Clinical and Proliferation Marker Study. J. Clin. Endocrinol. Metab. 82 (1997) 2102-2107
10. Fahy U.M., Foster P.A., Torode H.W., Hartog M., and Hull M.G. The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol. Endocrinol. 6 3 (1992) 183-188
11. Fujimoto N., Jinno N., and Kitamura S. Activation of estrogen response element dependent transcription by thyroid hormone with increase in estrogen receptor levels in rat pituitary cell line, GH3. J. Endocrinol. 181 (2004) 77-83
12. Fujimoto N., Igarashi K., Kanno J., Honda H., and Inoue T. Identification of estrogen-responsive genes in the GH3 cell line by cDNA micro-array analysis. J. Steroid Biochem. Mol. Biol. 91 (2004) 121-129
13. Goluboff L.G., and Ezrin C. Related Articles, Links. Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J. Clin. Endocrinol. Metab. 29 (1969) 1533-1538
14. Gomez O., and Balsa J.A. Autocrine/paracrine action of vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen. Endocrinology 144 (2003) 4403-4409
15. Heaney A.P., Horwitz G.A., Wang Z., Singson R., and Melmed S. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat. Med. 5 (1999) 1317-1321
16. Klibanski A., Neer R.M., Beitins I.Z., Ridgway E.C., Zervas N.T., and McArthur J.W. Decreased bone density in hyperprolactinemic women. N. Engl. J. Med. 303 (1980) 1511-1514
17. Kovacs K., Stefaneanu L., Ezzat S., and Smyth H.S. Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Arch. Pathol. Lab. Med. 118 (1994) 562-565
18. Kupersmith M.J., Rosenberg C., and Kleinberg D. Visual loss in pregnant women with prolactin adenomas. Ann. Intern. Med. 121 (1994) 473-477
19. Lee E.J., Duan W.R., Jakacka M., Gehm B.D., and Jameson J.L. Dominant negative ER induces apoptosis in GH(4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinology 142 (2001) 3756-3763
20. Lieberman M.E., Maurer R.A., and Gorski J. Estrogen control of prolactin synthesis in vitro. Proc. Natl. Acad. Sci. USA 75 (1978) 5946-5949
21. Lieberman M.E., Maurer R.A., Claude P., Wiklund J., Wertz N., and Gorski J. Regulation of pituitary growth and prolactin gene expression by estrogen. Adv. Exp. Med. Biol. 138 (1981) 151-163
22. Maurer R.A., Kim K.E., Day R.N., and Notides A.C. Regulation of prolactin gene expression by estradiol. Prog. Clin. Biol. Res. 322 (1990) 159-169
23. Molitch M.E. Management of prolactinomas during pregnancy. J. Reprod. Med. 44 (1999) 1121-1126
24. Molitch M. Pituitary tumors and pregnancy. Growth Horm. IGF Res. 13 (2003) S38-S44
25. Morales A., and Nickel J.C. Clinical relevance of plasma testosterone and prolactin changes in advanced prostate cancer of prostate treated with diethylstilbestrol or estramustine phosphate. Urology 26 (1985) 477-481
26. Morange I., Barlier A., Pellegrini I., Brue T., Enjalbert A., and Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur. J. Endocrinol. 135 (1996) 413-420
27. Munemura M., Agui T., and Sibley D.R. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland. Endocrinology 124 (1989) 346-355
28. Neill J.D., Freeman M.E., and Tillson S.A. Control of the proestrus surge of prolactin and luteinizing hormone secretion by estrogens in the rat. Endocrinology 89 (1971) 1448-1453
29. Prager D., and Braustein G.D. Pituitary disorders during pregnancy. Endocrinol. Metab. Clin. North Am. 24 (1995) 1-14
30. Rasmussen C., Bergh T., Nillios S.J., and Wide L. Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Fertil. Steril. 44 (1985) 31-34
31. Ricci E., Parazzini F., Motta T., Ferrari C.I., Colao A., Clavenna A., et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod. Toxicol. 16 (2002) 791-793
32. Robert E., Musatti L., Piscitelli G., and Ferrari C.I. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 10 (1996) 333-337
33. Scheithauer B.W., Sano T., Kovacs K.T., Young Jr. W.F., Ryan N., and Randall R.V. The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc. 65 (1990) 461-474
34. Schelchte J.A. Clinical practice: prolactinomas. N. Engl. J. Med. 349 (2003) 2035-2041
35. Shy K.K., McTiernan A.M., Daling J.R., and Weiss N.S. Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA 249 (1983) 2204-2207
36. Spady T.J., McComb, and Shull J.D. Estrogen action in the regulation of cell proliferation, cell survival and tumorigenesis in the rat anterior pituitary gland. Endocrine 11 (1999) 217-233
37. Stefaneanu L., Kovacs K., Horvath E., Lloyd R.V., Buchfelder M., Fahlbusch R., et al. In situ hybridization study of estrogen receptor messenger ribonucleic acid in human adenohypophysial cells and pituitary adenomas. J. Clin. Endocrinol. Metab. 78 (1994) 83-88
38. Strecker T.E., Spady T.J., Schaffer B.S., Gould K.A., Kaufman A.E., Shen F., et al. Genetic bases of estrogen-induced pituitary tumorigenesis: identification of genetic loci determining estrogen-induced pituitary growth in reciprocal crosses between the ACI and Copenhagen rat strains. Genetics 16 (2005) 2189-2197 (Epub 2005 Jan 31)
39. Testa G., Vegetti W., Motta T., Alagna F., Bianchedi D., Carlucci C., et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58 2 (1998) 69-73
40. Touraine P., Deneux C., Plu-Bureau G., Mauvais-Jarvis P., and Kuttenn F. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. J. Endocrinol. Invest. 21 11 (1998) 732-736
41. Verhelst J., Abs R., Maiter D., van den Bruel A., Vanderghe M., Velkeniers B., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84 (1999) 2518-2522